Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bbbiotech.com, you confirm that you have read, understood and accepted the general information provided by the BB Biotech AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions.

This website uses cookies, which are necessary for the technical operation of the website and which are always set. Other cookies to personalize content and analyze access to our website are only set with your consent. We also share information about your use of our website with our social media, advertising and analytics partners.

Foreword

  • Chairwoman of the Sustainability and Governance Committee

    Chairwoman of the Sustainability and Governance Committee

    Laura Hamill 

Dear reader,

Despite a challenging year on many fronts we are confident that investing in the biotechnology sector will achieve long-term success.

As an active investor, BB Biotech invests in a concentrated, high-conviction portfolio of biotech companies. The biotech companies’ products address areas of unmet medical needs and have high profit-growth potential as well as a significant positive impact on society. BB Biotech has a business-driven approach to sustainability. BB Biotech has a more than 30-year history of acting as an engaged and responsible investment company and are focusing on delivering long-term value to investors and society as a whole.

Over our more than 30 years of existence we have constantly developed our approach to responsible investing, and we are well aware that we still have much to learn and that this is a dynamic process. Engaging with portfolio companies on ESG is a journey and a constant learning process for all parties. By initiative from our Sustainability and Governance Committee we are gradually introducing new and meaningful ESG initiatives. Most recently we have implemented new policies regarding diversity, human rights, data privacy, political involvement, responsible marketing, anti-bribery and corruption, tax, health and safety and anti-money laundering. These policies and other relevant information are accessible on www.bbbiotech.ch.

In 2023 BB Biotech was selected by the Swiss Stock Exchange to be included in the SPI ESG Index. The index measures the development of Swiss equities based on an ESG rating metric provided by the rating agency Inrate.

 

In 2023 BB Biotech was selected by the Swiss Stock Exchange to be included in the SPI ESG Index.

 

We strive to keep all board members updated on recent developments regarding ESG and with this in mind we had an ESG training session conducted by Deloitte at our board meeting in November 2023.

The basic aim of biotechnology is to meet human needs or demands in order to improve quality of life and the sector ranks among the fastest growing industries. Among BB Biotech´s portfolio companies we saw several new approvals in 2023:

CompanyProductTreatment of
Incyte & MacrogenicsZynyzMerkel Cell Carcinoma
IonisQalsodySOD1 Amyotrophy Lateral Sclerosis
ArgenxVyvgart HytruloGeneralized Myasthenia Gravis
SageZuranolonePost Partum Depression
NeurocrineValbenaizineChorea Huntington
Crispr & VertexCasgevySickle Cell Disease
IonisWainuaPolyneuropathy of Hereditary 
Transthyretin-mediated Amyloidosis

 

Also in the future we are expecting the portfolio companies to contribute with several new drug approvals. Currently BB Biotech´s portfolio companies have a large number of product candidates in clinical development.

BB Biotech AG strives to be in the leading group of companies with respect to sustainability. That’s why sustainability is a priority for the Board of Directors.

We continue providing as much information and transparency on our processes and results as possible to give investors the information they need to succeed.

Sustainability